Form 4: Assembly Biosciences Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, sold 197 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On April 1, 2024, Nicole S. White, the Chief Manufacturing Officer of Assembly Biosciences, sold 197 shares of the company's common stock at a weighted average price of $13.0719.
- The shares were sold to cover tax withholding obligations related to the vesting and settlement of restricted stock units, as mandated by an administrative rule adopted by the Compensation Committee.
- The sale was not a discretionary transaction by the reporting person.
- White also received a grant of stock options for 17,500 shares on March 29, 2024, with an exercise price of $13.30.
- These options vest over four years, with 25% vesting on March 29, 2025, and the remaining 75% vesting in monthly installments until March 29, 2028.
- Following the reported transaction, White beneficially owns 10,947 shares of Assembly Biosciences common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reports a routine transaction to cover tax obligations. The grant of stock options is a positive sign, but the sale of shares is a neutral event in this context.
Positives
- The grant of stock options to the Chief Manufacturing Officer aligns her interests with the long-term success of the company.
- The vesting schedule of the stock options encourages continued service and commitment to Assembly Biosciences.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates that the Chief Manufacturing Officer is selling shares to cover tax obligations, which is a common practice.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.
Key Dates
| Date | Description |
|---|---|
| 02/09/2023 | 1-for-12 reverse stock split of the Issuer's common stock. |
| 03/29/2024 | Grant date of stock options for 17,500 shares. |
| 04/01/2024 | Date of sale of 197 shares of common stock. |
| 04/02/2024 | Date of signature on the Form 4 filing. |
| 03/29/2025 | First vesting date (25%) of the stock options. |
| 03/29/2028 | Final vesting date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.